IOncology

From August 27–31, 2025, the 16th Yan Zhao Breast Cancer Forum was held grandly in Shijiazhuang. The event was jointly organized by the Breast Cancer Committee of the Hebei Anti-Cancer Association and several other specialty committees, co-organized by the Beijing Breast Disease Prevention and Treatment Society, and hosted by the Fourth Hospital of Hebei Medical University and the Hebei Breast Disease Diagnosis and Treatment Center. This year’s forum focused on multidisciplinary innovations and cutting-edge concepts in breast cancer management, aiming to advance standardized care and elevate regional treatment standards. At the meeting, Oncology Frontier invited the conference chair, Professor Yunjiang Liu of the Fourth Hospital of Hebei Medical University, for an in-depth interview. He discussed the core principles of oncoplastic surgery (OPS) in breast-conserving surgery, shared clinical experience and outcomes from the multidisciplinary team (MDT) model, and offered forward-looking perspectives on promoting greater uniformity in breast cancer care across the region and nationwide.

Insights from the 2025 Pujiang Urologic Oncology Congress Editor’s Note: The 2025 Pujiang Urologic Oncology Congress was held in Shanghai from August 22–23 under the theme “Precision Breakthroughs · Integrated…

Fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) is a distinct pathological subtype of RCC characterized by a well-defined driver mutation and high malignancy. In recent years, studies have shown that…

The 2025 Beijing Breast Cancer Forum and Breast Reconstruction Symposium, held from June 25 to June 28 in Beijing, was hosted by the Beijing Society for Breast Disease Prevention and Treatment and co-organized by the Breast Center of Peking University People’s Hospital and the Jiaqing Breast Cancer Prevention Foundation. During the conference, Oncology Frontier invited Prof. Que Zhang, Vice President of the Beijing Society for Breast Disease Prevention and Treatment, to provide in-depth insights into the current challenges and future directions of early breast cancer screening in primary care institutions in China. He also reflected on the broader significance of the newly launched “Peking University People’s Hospital Jiaqing Foundation Centennial Legacy Training Program.”

At the 2025 ASCO Annual Meeting, two important studies—TRADE and OASIS-4—brought forward new treatment concepts and methods for early breast cancer, particularly in improving treatment adherence and patient quality of life. The TRADE study (Abstract No. 517) introduced a dose-escalation strategy for the CDK4/6 inhibitor abemaciclib in HR+/HER2− breast cancer patients, significantly improving adherence and tolerability. Meanwhile, the OASIS-4 study (Abstract No. 508) demonstrated, for the first time, the rapid onset and long-term safety of elinzanetant in alleviating vasomotor symptoms (VMS) caused by adjuvant endocrine therapy in HR+ breast cancer, offering a new option for enhancing quality of life and adherence. Oncology Frontier invited Prof. Songqing Ye of Fujian Provincial Hospital, affiliated with Fuzhou University, to provide in-depth insights into these two key studies.

At the 2025 ASCO Annual Meeting, the West German Study Group (WSG) presented a pooled analysis (Abstract No. 502) of three trials—including the ADAPT TP study—exploring survival outcomes following chemotherapy de-escalation in HER2-positive early breast cancer (eBC). Oncology Frontier invited Prof. Jia Wang and Dr. Jinze Yu from the Second Affiliated Hospital of Dalian Medical University to interpret and comment on the findings for our readers.

There is currently no universally accepted standard treatment for patients who progress after receiving CDK4/6 inhibitors combined with endocrine therapy (CDK4/6i + ET). In the era of precision medicine, both domestic and international guidelines increasingly recommend biomarker-driven treatment strategies. However, the population covered by each biomarker is often limited, creating an urgent clinical need for more potent and broadly applicable therapies that can simplify both diagnostic testing and treatment selection.

The “YBCSG 2025 Mid-Year Breast Cancer Collaboration Meeting and Post-ASCO Symposium,” held recently in Shanghai, gathered experts to discuss clinical updates in breast cancer treatment. At the event, Prof. Hengyu Li—Secretary General of the Yangtze River Breast Cancer Study Group (YBCSG) and a leading expert at Shanghai Changhai Hospital, Naval Medical University—delivered a comprehensive presentation titled “Treatment Challenges of Breast Cancer Liver Metastases in 2025.” In an exclusive interview with Oncology Frontier, Prof. Li elaborated on YBCSG’s major achievements in the first half of 2025 and highlighted key challenges in managing liver metastases in breast cancer.